MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.

ABSTRACT:

Purpose

MET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in MET exon 14-altered lung cancers, likely secondary to primary resistance. Mechanisms of primary resistance remain poorly characterized and comprehensive proteomic analyses have not previously been performed.

Experimental design

We performed hybrid capture-based DNA sequencing, targeted RNA sequencing, cell-free DNA sequencing, selected reaction monitoring mass spectrometry (SRM-MS), and immunohistochemistry on patient samples of MET exon 14-altered lung cancers treated with a MET TKI. Associations between overall response rate (ORR), progression-free survival (PFS), and putative genomic alterations and MET protein expression were evaluated.

Results

Seventy-five of 168 <

SUBMITTER: Guo R 

PROVIDER: S-EPMC7854494 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature